Here are the key details of the round:
Please note that this extension is exclusive to current investors and will close once the final patient is enrolled—estimated for the end of March.
Impact and Milestones
Securing the full $675K will provide us with the necessary runway through August/September 2026, and will allow us to complete lengthy pre-FDA activities (such as the Human Factors study) in parallel rather than sequentially. Most importantly, it will allow us to reach our next major inflection points: completing our clinical study and achieving FDA submission.
Projected Valuation Impact
By successfully hitting these clinical and regulatory milestones, we believe our valuation will increase to the $20M – $25M range, based on current market comparables and recent venture feedback. (Of course, we recognize that a lead investor for the next round will ultimately dictate those terms.)
We welcome any additional questions you might have as you discuss this internally, and we are so grateful for the ongoing support of the OSEIN angel community.
Would you like me to send over any additional financial models or clinical study timelines to help with your review process?
Use of Prior Funding
Validation and Progress